Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils.

Zhou SL, Dai Z, Zhou ZJ, Chen Q, Wang Z, Xiao YS, Hu ZQ, Huang XY, Yang GH, Shi YH, Qiu SJ, Fan J, Zhou J.

Carcinogenesis. 2014 Mar;35(3):597-605. doi: 10.1093/carcin/bgt397. Epub 2013 Nov 30.

PMID:
24293410
2.

Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma.

Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, Huang XW, Fan J, Zhou J.

Hepatology. 2012 Dec;56(6):2242-54. doi: 10.1002/hep.25907.

PMID:
22711685
3.

Identification of CXCL5/ENA-78 as a factor involved in the interaction between cholangiocarcinoma cells and cancer-associated fibroblasts.

Okabe H, Beppu T, Ueda M, Hayashi H, Ishiko T, Masuda T, Otao R, Horlad H, Mima K, Miyake K, Iwatsuki M, Baba Y, Takamori H, Jono H, Shinriki S, Ando Y, Baba H.

Int J Cancer. 2012 Nov 15;131(10):2234-41. doi: 10.1002/ijc.27496. Epub 2012 Mar 27.

4.

Intratumoral IL-17⁺ cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma.

Gu FM, Gao Q, Shi GM, Zhang X, Wang J, Jiang JH, Wang XY, Shi YH, Ding ZB, Fan J, Zhou J.

Ann Surg Oncol. 2012 Aug;19(8):2506-14. doi: 10.1245/s10434-012-2268-8. Epub 2012 Mar 13.

PMID:
22411204
5.

A high level of integrin α6 expression in human intrahepatic cholangiocarcinoma cells is associated with a migratory and invasive phenotype.

Ding YB, Deng B, Huang YS, Xiao WM, Wu J, Zhang YQ, Wang YZ, Wu DC, Lu GT, Wu KY.

Dig Dis Sci. 2013 Jun;58(6):1627-35. doi: 10.1007/s10620-012-2524-6. Epub 2013 Jan 11.

PMID:
23306848
6.

High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery.

Shi RY, Yang XR, Shen QJ, Yang LX, Xu Y, Qiu SJ, Sun YF, Zhang X, Wang Z, Zhu K, Qin WX, Tang ZY, Fan J, Zhou J.

Cancer. 2013 Mar 1;119(5):993-1003. doi: 10.1002/cncr.27788. Epub 2012 Nov 6.

7.

Fatty acid-binding protein 5 promotes cell proliferation and invasion in human intrahepatic cholangiocarcinoma.

Jeong CY, Hah YS, Cho BI, Lee SM, Joo YT, Jung EJ, Jeong SH, Lee YJ, Choi SK, Ha WS, Park ST, Hong SC.

Oncol Rep. 2012 Oct;28(4):1283-92. doi: 10.3892/or.2012.1922. Epub 2012 Jul 19.

PMID:
22825302
8.

Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma.

Sulpice L, Rayar M, Desille M, Turlin B, Fautrel A, Boucher E, Llamas-Gutierrez F, Meunier B, Boudjema K, Clément B, Coulouarn C.

Hepatology. 2013 Dec;58(6):1992-2000. doi: 10.1002/hep.26577. Epub 2013 Oct 17.

PMID:
23775819
9.

The potential of CXCL5 as a target for liver cancer - what do we know so far?

Xia J, Xu X, Huang P, He M, Wang X.

Expert Opin Ther Targets. 2015 Feb;19(2):141-6. doi: 10.1517/14728222.2014.993317. Epub 2014 Dec 11.

PMID:
25495348
10.

Roles of CXCL5 on migration and invasion of liver cancer cells.

Xu X, Huang P, Yang B, Wang X, Xia J.

J Transl Med. 2014 Jul 10;12:193. doi: 10.1186/1479-5876-12-193.

11.

CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer.

Kawamura M, Toiyama Y, Tanaka K, Saigusa S, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y, Kusunoki M.

Eur J Cancer. 2012 Sep;48(14):2244-51. doi: 10.1016/j.ejca.2011.11.032. Epub 2011 Dec 24.

PMID:
22197219
12.

Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma.

Suzuki S, Sakaguchi T, Yokoi Y, Okamoto K, Kurachi K, Tsuchiya Y, Okumura T, Konno H, Baba S, Nakamura S.

World J Surg. 2002 Jun;26(6):687-93. Epub 2002 Mar 26.

PMID:
12053220
13.

Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion.

Ye Y, Zhou L, Xie X, Jiang G, Xie H, Zheng S.

J Surg Oncol. 2009 Nov 1;100(6):500-4. doi: 10.1002/jso.21376.

PMID:
19697355
14.

Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type.

Aishima S, Kuroda Y, Nishihara Y, Iguchi T, Taguchi K, Taketomi A, Maehara Y, Tsuneyoshi M.

Am J Surg Pathol. 2007 Jul;31(7):1059-67.

PMID:
17592273
15.

Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients.

Speetjens FM, Kuppen PJ, Sandel MH, Menon AG, Burg D, van de Velde CJ, Tollenaar RA, de Bont HJ, Nagelkerke JF.

Clin Cancer Res. 2008 Apr 15;14(8):2276-84. doi: 10.1158/1078-0432.CCR-07-4045.

16.

Down-regulation of CXCL5 inhibits squamous carcinogenesis.

Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS, Yeudall WA.

Cancer Res. 2006 Apr 15;66(8):4279-84.

17.

Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.

Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A, Nicoli P, Cappellani A, Malfermoni G, Iacono C.

World J Surg. 2009 Jun;33(6):1247-54. doi: 10.1007/s00268-009-9970-0.

PMID:
19294467
18.

Combined hepatocellular-cholangiocarcinoma had poor outcomes after hepatectomy regardless of Allen and Lisa class or the predominance of intrahepatic cholangiocarcinoma cells within the tumor.

Ariizumi S, Kotera Y, Katagiri S, Nakano M, Yamamoto M.

Ann Surg Oncol. 2012 May;19(5):1628-36. doi: 10.1245/s10434-011-2150-0. Epub 2011 Nov 24.

PMID:
22113592
19.

Decreased roundabout 1 expression promotes development of intrahepatic cholangiocarcinoma.

Mano Y, Aishima S, Fukuhara T, Tanaka Y, Kubo Y, Motomura T, Toshima T, Iguchi T, Shirabe K, Maehara Y, Oda Y.

Hum Pathol. 2013 Nov;44(11):2419-26. doi: 10.1016/j.humpath.2013.03.022. Epub 2013 Aug 15.

PMID:
23953227
20.

CXCL5 knockdown expression inhibits human bladder cancer T24 cells proliferation and migration.

Zheng J, Zhu X, Zhang J.

Biochem Biophys Res Commun. 2014 Mar 28;446(1):18-24. doi: 10.1016/j.bbrc.2014.01.172. Epub 2014 Feb 26.

PMID:
24583128

Supplemental Content

Support Center